By Dr. Abeer Elsayed Aly Lecturer of medical oncology SECI 18/3/2013

Slides:



Advertisements
Similar presentations
Regional Perspectives on Renal Cell Carcinoma Mohamed Abdulla M.D. Professor of Clinical Oncology Cairo University AfME. September 17 th 2010W:
Advertisements

The Basics Of Cancer* By Aoife Rafferty* Catherine Quaile* Kayleigh Powderly*
Mizutomo Azuma 1, Michael M. Shi 2, Christian J. Jacques 2, Carl Barrett 2, Kathleen D. Danenberg 3, Syma Iqbal 1, Anthony El-Khoueiry 1, Dongyun Yang.
Cancer.
Renal Tumours n Mr C Dawson MS FRCS n Consultant Urologist n Fitzwilliam Hospital n Peterborough.
Von Hippel-Lindau Syndrome (VHL) Presented by Kelley Montoya March 20, 2003.
Management of T1 Kidney Cancer Laparoscopic Surgery
von Hippel-Lindau Syndrome (VHL)
Chapter 19 Cancer and the Immune System Dr. Capers.
Molecular Biology of kidney cancers
Targeted Therapy for Renal Cell Cancer Dr.MahmoodzadehOncologist-Hematologist.
Genomics Lecture 7 By Ms. Shumaila Azam. Tumor Tumor – abnormal proliferation of cells that results from uncontrolled, abnormal cell division A tumor.
Adjuvant therapy for renal cell carcinoma Dr.Mina Tajvidi oncologist.
Urinary Tract Tumors 2%-3% of all cancers in adults. The most common malignant tumor of the kidney is renal cell carcinoma. followed in frequency by nephroblastoma.
Urinary tract pathology-2. Renal Cell Carcinoma RCC account for 2% to 3% of all cancers in adults and are classified into three major types: Clear cell.
3.1.3.A Understanding Cancer What is Cancer.
Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas. Wiesener.
Copyright © 2006 Pearson Education, Inc. publishing as Benjamin Cummings.
Dr. Ziad W Jaradat Cancer Stem Cells. Recently biologically distinct and relatively rare populations of tumor-initiating cells have been identified in.
Chapter 21 Cancer and the Immune System Dr. Capers
The Function of VHL and pVHL Protein VHL is a tumor suppressor gene on chromosome 3 Helps to regulate and destroy the alpha subunit of hypoxia-inducible.
Dr Francis Daniel, MB. ChB, FFR-RCSI, FRCR. Consultant in Clinical Oncology
1 Tumors of Urinary Tract. 2 Urinary Tract Neoplasm KidneyRenal Cell Carcinoma [ adult], Transitional cell carcinoma [ adult], Wilms Tumor [children]
Ishita Das
Javad Jamshidi Fasa University of Medical Sciences, November 2015 Session 9 Medical Genetics Cancer Genetics.
Javad Jamshidi Fasa University of Medical Sciences, December 2015 Cancer Genetics Session 4 Medical Genetics.
Raafat R. Abdel-Malek, MD, FRCR Ass. Prof Clinical Oncology Cairo University, Egypt Efficacy & Toxicity of Sunitinib in mRCC patients in Egypt.
Radical vs Partial Nephrectomy for treatment of renal cell carcinoma at Prince Hussein Urology Centre Dr. Mohammad Alserhan Urology specialist Prince Hussein.
Renal cell carcinoma R4 신재령 Clinical Practice Guidelines for the Treatment of Metastatic Renal Cell Carcinoma.
Prepared by : Dr. Nehad J. Ahmed. Cancer is a disease that results from abnormal growth and differentiation of tissues. Tumor or neoplasm - A mass of.
Cancer What is cancer? uncontrolled cell growth that leads to the formation of primary tumors cells that spread (metastasize) to other areas of the body.
Treatment for Cancer. Surgery Treatment and prognosis depend on severity and spread of the cancer Treatment and prognosis depend on severity and spread.
Prof. Jae Heon, Jeong/R2 Cheol Hyun, Lee J of Clinical oncology, Vol 31 Number 4, Feb.1, 2013.
SURGICAL ONCOLOGY AND TUMOR MARKERS
Dr.Amit Gupta Associate Professor Dept. of Surgery
Von Hippel-Lindau Syndrome
Molecular Dissection of Complete Response to Receptor Tyrosine Kinase Inhibition in Type II Papillary Renal Cell Carcinoma  Matti Annala, Lucia Nappi,
Cancer progresses through accumulation of multiple mutations
Characterization of VHL promoter variants in patients suspected of Von Hippel Lindau Saleh Albanyan, Rachel Giles, Raymond H Kim, MD/PhD Division of.
Dr. Peter John M.Phil, PhD Atta-ur-Rahman School of Applied Biosciences (ASAB) National University of Sciences & Technology (NUST)
Arne R. M. van der Bilt, Elisabeth G. E
Targeting HIF2α in Clear-Cell Renal Cell Carcinoma
Systemic Therapies in Renal Cell Carcinoma
VHL & von Hippel-Lindau syndrome
Hereditary Gastrointestinal Cancers
Volume 76, Issue 9, Pages (November 2009)
Hemangioblastoma Intern 蔡佽學.
Tumors of kidney and urinary bladder
Two HIFs may be better than one
Inducing Angiogenesis
Cancer.
Renal Cell Carcinoma: Prognostic Factors and Patient Selection
and multiple endocrine neoplasia type 2 (MEN2)
von Hippel-Lindau Disease
Focus on hereditary endocrine neoplasia
New Research on Kidney Cancer: Highlights from Urologic and Oncologic Congresses in 2006  Jean-Jacques Patard, Eric Lechevallier, Belén Congregado Ruiz,
M.B.Ch.B, MSC, DCH (UK), MRCPCH
PTEN (a.k.a. MMAC1 and TEP1) and Cowden’s Disease
Dan Gordon  Gastroenterology  Volume 114, Issue 4, (April 1998)
Management of advanced renal cancer
Basic Research in Kidney Cancer
Nat. Rev. Nephrol. doi: /nrneph
Genetic Changes & Biotechnology
Current and Future Trends in the Treatment of Renal Cancer
Understanding the Importance of Smart Drugs in Renal Cell Carcinoma
Targeting HIF2α in Clear-Cell Renal Cell Carcinoma
Volume 76, Issue 9, Pages (November 2009)
M.B.Ch.B, MSC, PhD, DCH (UK), MRCPCH
Objectives: 1. Cancer and the cell cycle checkpoints, reqmts to advance oncogenes tumor suppressor genes 2. 6 Traits of cancerous cells 3. Facts on.
Update on the Medical Treatment of Metastatic Renal Cell Carcinoma
Presentation transcript:

By Dr. Abeer Elsayed Aly Lecturer of medical oncology SECI 18/3/2013 Renal cell carcinoma By Dr. Abeer Elsayed Aly Lecturer of medical oncology SECI 18/3/2013

von Hippel-Lindau syndrome Autosomal dominant Multiple cancers RCC in nearly 40% of patients del (3p) or t (3;6) or t (3;8) => VHL gene (3p26-p25) mutated => accumulation of hypoxia inducible factors (HIFs) that stimulate angiogenesis through VEGF and VEGFR

Hereditary papillary renal carcinoma AD bilateral, multifocal papillary renal carcinoma Germline missense mutations in the tyrosine kinase domain of the MET gene (7q31) => constitutive activation TFE3 mutation t(X;1)(p11;q21)

MET β-subunit of c-Met product is the cell-surface receptor for hepatocyte growth factor amplified during the transition between primary tumors and metastasis metastatic potential relies on the properties of its multifunctional docking site PRC commonly show trisomy of ch.7

Familial renal oncocytoma usually benign tumors Ultrastructural characterization exhibits dense packing of the cells with mitochondria that show morphologic differences from those in normal cells [larger, abnormally shaped] Mutation in mtDNA within the CyC oxidase subunit I gene

BIRT-HOGG-DUBE SYNDROME BHD gene 17p11.2 [TS] Adult onset male-to-male transmission

Treatment of early stages

Nephrectomy

What about adjuvant therapy?

Treatment of metastatic disease

Immunotherapy IL2 interferon alpha

Alpha-methylacyl-CoA racemase significant increase of AMACR mRNA levels in papillary renal cell carcinomas only Also molecular marker for prostate cancer B7-H1 expression may indicate worse survival, possibly through impaired host antitumor immunity Microsatellite instabilities

Target Therapy What is my the target?

Temsirolimus

Bevaciziumab

Pazopanib

Vaccine

Reduced inteinsty myeloablative bone marrow transplant

Summary

Thank You